Moderna (MRNA) Expected to Announce Earnings on Friday

Key Points

• Q1 2026 earnings are scheduled before the market opens on Friday, May 1 (conference call 8:00 AM ET), with analysts projecting ($2.03) EPS and about $251.0M in revenue.
• Moderna last reported ($2.11) EPS and $678M revenue (beating estimates) but revenue fell 33.2% YoY; analysts still forecast large FY losses (consensus ~-7 EPS this year, ~-4 next) and a MarketBeat consensus target of $33.87 ("Reduce").
• Near‑term catalysts include EU approval of mCOMBRIAX and a Phase 3 bird‑flu trial, but the company faces headwinds from negative margins, past U.S. funding cuts for the bird‑flu program, and recent insider selling.

Moderna (NASDAQ:MRNA - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Friday, May 1st. Analysts expect the company to announce earnings of ($2.03) per share and revenue of $251.0050 million for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 1, 2026 at 8:00 AM ET.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.79) by $0.68. The firm had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The business's revenue for the quarter was down 33.2% on a year-over-year basis. During the same period in the prior year, the business earned ($2.91) EPS. On average, analysts expect Moderna to post $-7 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Moderna Stock Down 4.9%

Shares of Moderna stock opened at $52.85 on Friday. The stock has a 50-day moving average price of $51.57 and a 200 day moving average price of $38.59. The company has a market cap of $20.87 billion, a P/E ratio of -7.27 and a beta of 1.33. The company has a current ratio of 3.29, a quick ratio of 3.22 and a debt-to-equity ratio of 0.07. Moderna has a 1 year low of $22.28 and a 1 year high of $59.55.

Insider Buying and Selling

In related news, President Stephen Hoge sold 160,009 shares of the business's stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president directly owned 1,457,427 shares of the company's stock, valued at approximately $71,180,734.68. The trade was a 9.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 10.80% of the company's stock.

Institutional Trading of Moderna

Large investors have recently added to or reduced their stakes in the business. Empowered Funds LLC boosted its holdings in Moderna by 2.6% in the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company's stock valued at $405,000 after acquiring an additional 353 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Moderna by 21.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company's stock valued at $63,000 after acquiring an additional 387 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund boosted its holdings in Moderna by 6.2% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 9,334 shares of the company's stock valued at $241,000 after acquiring an additional 546 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Moderna by 5.1% in the fourth quarter. Mackenzie Financial Corp now owns 11,767 shares of the company's stock valued at $357,000 after acquiring an additional 566 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its holdings in Moderna by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 110,812 shares of the company's stock valued at $2,862,000 after acquiring an additional 687 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Evercore set a $35.00 price objective on shares of Moderna in a research report on Tuesday, February 17th. The Goldman Sachs Group boosted their price objective on shares of Moderna from $36.00 to $41.00 and gave the company a "neutral" rating in a research report on Tuesday, February 17th. Royal Bank Of Canada boosted their price objective on shares of Moderna from $25.00 to $30.00 and gave the company a "sector perform" rating in a research report on Tuesday, February 17th. BMO Capital Markets raised shares of Moderna from a "market perform" rating to a "buy" rating in a research report on Monday, January 12th. Finally, Morgan Stanley set a $30.00 price objective on shares of Moderna in a research report on Monday, February 16th. Two equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have given a Sell rating to the company's stock. According to data from MarketBeat.com, Moderna has a consensus rating of "Reduce" and a consensus target price of $33.87.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: European Commission approval of mCOMBRIAX (Moderna’s COVID‑19 + influenza combination vaccine) gives Moderna a near‑term commercial product with strong phase 3 data supporting uptake in Europe. This is a clear revenue catalyst and was a driver of recent upside in the stock. Read More.
• Positive Sentiment: Moderna has initiated a large Phase 3 trial of its mRNA‑1018 (bird‑flu) vaccine — now supported by CEPI and proceeding in the U.S. and U.K. — which, if successful, would create another high‑value vaccine franchise and reduce pandemic risk exposure. Read More.
• Neutral Sentiment: Coverage notes that repeat vaccination data for Moderna’s seasonal mRNA candidates (mRNA‑1010 series) show acceptable safety/reactogenicity, supporting ongoing product rollouts but not guaranteeing uptake. Read More.
• Neutral Sentiment: Moderna saw a short‑term share lift on April 22 after the EU approval and related news; some of today’s weakness looks like profit‑taking following that run. Read More.
• Negative Sentiment: The U.S. Department of Health and Human Services canceled funding for Moderna’s bird‑flu program earlier, which forced the company to secure alternative support (e.g., CEPI). The funding loss increases execution and reimbursement risk in the U.S. and has been flagged by analysts and reporters as a headwind. Read More.
• Negative Sentiment: Fundamentally, Moderna still faces steep year‑over‑year revenue declines from the pandemic trough, negative margins and consensus estimates projecting sizable FY losses — factors that cap valuation upside until sustainable, diversified revenue streams materialize.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.